Corporate Earnings

Research and development expense was $20.7 million, up $9.9 million from $10.9 million a year earlier. Direct spending on atebimetinib came to $13.6 million versus $5.1 million, and the company attributed $8.5 million of the increase to running the MAPKeeper 301 trial.

Reported orders reached $2,345 million, up 21%, with organic orders up 18%. Chairman and CEO Vicente Reynal described a strongerDemandenvironment, with healthy activity across geographies and end markets.

Net sales were $15,220 million, up from $12,604 million, an increase of 20.8% that came from growth in every region. Advanced Solutions rose 40%, Client and Endpoint Solutions rose 10%, Cloud-based Solutions rose 31% and Other services rose 35%. The 2025 sale of the …

Revenue was $265.1 million, up from $244.9 million in the second quarter and $240.0 million in the third quarter of 2025. On a calculated basis, that is growth of about 8.2% sequentially and 10.4% year over year.

Intel Products revenue grew 22%, led by theData Centerand AI group, where revenue rose 78% to $7.3 billion on a richer mix of premium products and, to a lesser extent, demand-based pricing actions. Client Computing revenue came to $8.1 billion, down 5% on lower …

The swing came from other income. Total other loss reached $124.4 million, made up of a $402.1 million loss on investments partly offset by a $277.7 million gain on derivative instruments. The CEO said financial conditions tightened as investors priced in more Federal Reserve …

The company added a record 9,500 net locations in the second quarter, taking the base to about 180,000, up 22 percent, and gross paymentVolumerose 22 percent. Subscription annualized recurring revenue was USD 1.21 billion and payments annualized recurring revenue was USD 1.20 billion, each …